Urine iodine excretion in patients with papillary thyroid cancer evaluation of the relationship with the presence of BRAF mutation
Marzec 06, 2020
Maj 16, 2020
Celik M., Guldiken S., Salt S.A., Bulbul B.Y., Kucukarda A., Can N., Tastekin E., Sezer A., Sut N., Tugrul A., Gurkan H., Tozkir H., Demirkan B.
Iodine is an essential element for the production of thyroid hormones. In recent years, it has been suggested that excessive consumption of iodine may play a role in the pathogenesis of papillary thyroid cancer (PTC). In addition, studies have suggested that high iodine consumption is an important risk factor for the formation of a BRAF mutation in the thyroid gland. A prospectively designed study included 132 cases scheduled for thyroidectomy for various reasons. Urine iodine levels of all patients were examined before the operation. The iodine excretion levels of the patients were grouped according to the median urinary iodine concentration determined in community screenings (those with <100 μg L-1 low iodine excretion, those with 100-199 μg L-1 normal iodine excretion, those with 200-299 μg L-1 high iodine excretion). Patients were divided into 3 groups according to the post-operative pathology results. As a result of thyroid histopathology, benign (n: 44), PTC (n: 88) (BRAF (+): 44 and BRAF (-): 44) cases were included in the study. BRAF mutations in patients diagnosed with PTC were evaluated using the "Real Time PCR Melting Curve Analyzer" method. The relationship between urinary iodine excretion levels and clinical, histopathological and BRAF positivity was examined. In our study, no difference was found in urinary iodine excretion between patients with and without PTC. Hashimoto’s thyroiditis was observed more frequently in patients with PTC (p = 0.023). In addition, Hashimoto’s thyroiditis was statistically more frequently detected in the BRAF (-) group compared to the BRAF (+) and control group (p = 0.034). Despite studies suggesting that high iodine consumption is important in PTC pathogenesis, we did not find a relationship between the mutation and iodine consumption, which plays an important role in the development of PTC.
Celik M., Guldiken S., Salt S.A., Bulbul B.Y., Kucukarda A., Can N., Tastekin E., Sezer A., Sut N., Tugrul A., Gurkan H., Tozkir H., Demirkan B. 2020. Urine iodine excretion in patients with papillary thyroid cancer evaluation of the relationship with the presence of BRAF mutation. J. Elem., 25(3): 1019 - 1028. DOI: 10.5601/jelem.2020.25.1.1984
papillary thyroid cancer, BRAF mutation, urine iodine excretion